Qiagen NV
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $41.655
- Today's High:
- $42.36
- Open Price:
- $42.29
- 52W Low:
- $40.38
- 52W High:
- $51.18
- Prev. Close:
- $42.45
- Volume:
- 961424
Company Statistics
- Market Cap.:
- $9.69 billion
- Book Value:
- 15.88
- Revenue TTM:
- $1.98 billion
- Operating Margin TTM:
- 23%
- Gross Profit TTM:
- $1.44 billion
- Profit Margin:
- 24.73%
- Return on Assets TTM:
- 4.55%
- Return on Equity TTM:
- 14.18%
Company Profile
Qiagen NV had its IPO on 1996-06-28 under the ticker symbol QGEN.
The company operates in the Healthcare sector and Diagnostics & Research industry. Qiagen NV has a staff strength of 6,100 employees.
Stock update
Shares of Qiagen NV opened at $42.29 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $41.66 - $42.36, and closed at $41.84.
This is a -1.44% slip from the previous day's closing price.
A total volume of 961,424 shares were traded at the close of the day’s session.
In the last one week, shares of Qiagen NV have slipped by -6.21%.
Qiagen NV's Key Ratios
Qiagen NV has a market cap of $9.69 billion, indicating a price to book ratio of 3.4048 and a price to sales ratio of 5.1004.
In the last 12-months Qiagen NV’s revenue was $1.98 billion with a gross profit of $1.44 billion and an EBITDA of $551.00 million. The EBITDA ratio measures Qiagen NV's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Qiagen NV’s operating margin was 23% while its return on assets stood at 4.55% with a return of equity of 14.18%.
In Q2, Qiagen NV’s quarterly earnings growth was a negative -16.7% while revenue growth was a negative 4%.
Qiagen NV’s PE and PEG Ratio
- Forward PE
- 23.753
- Trailing PE
- 28.3
- PEG
- 8.4627
Its diluted EPS in the last 12-months stands at $1.5 per share while it has a forward price to earnings multiple of 23.753 and a PEG multiple of 8.4627. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Qiagen NV’s profitability.
Qiagen NV stock is trading at a EV to sales ratio of 5.2709 and a EV to EBITDA ratio of 14.0863. Its price to sales ratio in the trailing 12-months stood at 5.1004.
Qiagen NV stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $6.35 billion
- Total Liabilities
- $978.45 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $31.13 million
- Dividend Payout Ratio
- 0%
Qiagen NV ended 2024 with $6.35 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $6.35 billion while shareholder equity stood at $3.62 billion.
Qiagen NV ended 2024 with $0 in deferred long-term liabilities, $978.45 million in other current liabilities, 2702000.00 in common stock, $1.87 billion in retained earnings and $2.46 billion in goodwill. Its cash balance stood at $609.55 million and cash and short-term investments were $1.33 billion. The company’s total short-term debt was $500,149,000 while long-term debt stood at $1.39 billion.
Qiagen NV’s total current assets stands at $2.31 billion while long-term investments were $0 and short-term investments were $722.35 million. Its net receivables were $312.60 million compared to accounts payable of $83.94 million and inventory worth $391.99 million.
In 2024, Qiagen NV's operating cash flow was $0 while its capital expenditure stood at $31.13 million.
Comparatively, Qiagen NV paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $41.84
- 52-Week High
- $51.18
- 52-Week Low
- $40.38
- Analyst Target Price
- $52.04
Qiagen NV stock is currently trading at $41.84 per share. It touched a 52-week high of $51.18 and a 52-week low of $51.18. Analysts tracking the stock have a 12-month average target price of $52.04.
Its 50-day moving average was $44.94 and 200-day moving average was $46.62 The short ratio stood at 2.6 indicating a short percent outstanding of 0%.
Around 36.7% of the company’s stock are held by insiders while 7162.3% are held by institutions.
Frequently Asked Questions About Qiagen NV
Similar Industry Stocks (Diagnostics & Research)
Most Active
Top Gainers
Top Losers
About
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.